ClinicalTrials.gg
RecruitingNCT06504160Updated Jul 2, 2026

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

A Phase 1 interventional study of ShA9 Topical Gel and Hydrocortisone Ointment in Atopic Dermatitis, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Recruiting at 8 sites in United States. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Dermatitis, Atopic by National Institute of Allergy and Infectious Diseases (NIAID) — 8 open to participants now, 9 under way, none of them phase 3. Dermatitis, Atopic · National Institute of Allergy and Infectious Diseases (NIAID).

Planned enrollment
5th of 16
86 · median 63
Started
2025
with 2 others
Phase 1
6 of 35
2 open now
Registered
32nd of 35
by date

Among the 35 studies in Dermatitis, Atopic by National Institute of Allergy and Infectious Diseases (NIAID), this one is the 5th largest by planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2025, is one of 6 in phase 1, and was the 32nd registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

8 of the 35 studies in Dermatitis, Atopic by National Institute of Allergy and Infectious Diseases (NIAID) are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Dermatitis, Atopic by National Institute of Allergy and Infectious Diseases (NIAID), or all of them as a file.
02

Study summary

This is a Phase 1b, randomized, placebo/vehicle-controlled, double-blinded, multi-center trial. It is designed to assess the safety and efficacy of S. hominis A9 (ShA9) topical application as a treatment for atopic dermatitis (AD). The trial will enroll adults and pediatric participants with atopic dermatitis.

The primary safety objective of this study is to compare the safety profile of ShA9 to placebo (vehicle) over 14 weeks of application, which includes an initial two-week period of co-treatment with topical corticosteroids (TCS). The primary efficacy objective of this study is to assess the ability of ShA9, compared to placebo (vehicle), to prolong the period of atopic dermatitis control over 12 weeks after conclusion of an initial two-week period of co-treatment with TCS.

Read the detailed description

Protocol ADRN-14 TIME-2 is a Phase 1b, randomized, placebo/vehicle-controlled, double-blinded, multi-center trial designed to assess the safety and efficacy of ShA9 topical application as a treatment for AD. This study will aim to enroll approximately 86 participants; participants must be 6 years of age or older and have AD.

An individual participant's involvement in this study will take approximately 20 weeks to complete, including approximately 2 weeks of screening, 14 weeks of treatment, and 4 weeks of safety follow-up.

An initial screening visit will be conducted to evaluate eligibility and to assess skin swabs collected from each participant for the presence of S. Aureus. Eligible participants will then begin an approximately 14-day period of standardized skin care by using over-the-counter products (e.g., Dove soap, Cetaphil moisturizer) which will be distributed from the study clinic. This is done to establish an informative baseline and allow for washout of any prohibited medications.

Participants who continue to meet eligibility criteria will then be randomized 1:1 to use either ShA9 gel or placebo (vehicle) gel for treatment of AD. Following randomization, for two weeks, each participant will receive co-treatment using TCS together with their assigned study product (active or placebo). Participants will then continue using their assigned study product without TCS for 12 more weeks. Participants will be seen in clinic approximately every 4 weeks during this time for sample/data collection and safety monitoring. Participants may be seen in clinic for additional visits to address any skin exacerbations while enrolled.

Participation concludes with a 4-week safety follow-up period during which use of ShA9 or placebo (vehicle) gel is halted. Participants will continue using over-the-counter products provided by the study clinic, as needed, while avoiding prohibited medications, and will be monitored for skin exacerbations and other adverse events.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • atopic dermatitis
  • eczema
  • ADRN
  • TIME-2
  • microbiome
  • Staphylococcus hominis
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Each individual must meet all of the following criteria at Screening to be eligible for enrollment as a study participant:

  1. Participant and/or parent/legal guardian must be able to understand and provide and assent (if applicable).
  2. Male or female participant 6 years of age or older.
  3. Meet ADRN Standard Diagnostic Criteria for active AD.

    Each individual must meet all of the following criteria at Baseline to be eligible for enrollment as a study participant:

  4. Have at least 7 cm2 of lesional skin within the upper extremities, lower extremities, and/or trunk. Lesions on the face, neck, hands, feet, and intertriginous areas do not count toward the required area, as samples may not be taken from these areas. The required area may be one contiguous area or may be comprised of multiple areas with a compliant total area.
  5. Have at least 3% body surface area of AD involvement as indicated by derived total area of involvement score during SCORAD assessment.
  6. Have an IGA score of two or greater.
  7. Each potential participant who can become pregnant must meet either of the following criteria prior to randomization to be eligible for enrollment as a study participant.

    1. Willing to remain abstinent from intercourse that may result in a pregnancy.
    2. Willing to use an FDA-approved method of for the duration of study participation. Acceptable methods include the following:

      • Permanent sterilization of partner
      • Long-acting reversible contraceptives (e.g., intrauterine devices or systems, implantable rods, contraceptive injections) when used as directed for at least 7 days prior to Baseline.
      • Short-acting hormonal contraceptives (e.g., oral contraceptive pills, patch, vaginal ring) when used as directed for at least 30 days prior to Baseline
      • Barrier methods (e.g., condoms; diaphragm, sponge, or cervical cap with spermicide)
  8. Have obtained negative pregnancy test results during both the Screening and Baseline Visits.

Exclusion criteria

Exclusion Criteria:

Individuals who meet any of the following criteria at Screening or Baseline are not eligible for enrollment as study participants:

  1. Inability or unwillingness to give written or comply with study protocol.
  2. Has self-reported as pregnant or lactating during the Screening or Baseline Visit, or is pregnant as indicated by a positive pregnancy test result obtained at the Screening or Baseline Visit.
  3. Sensitivity to or difficulty tolerating Dove® fragrance-free bar soap, Cetaphil® lotion, alcohol-based cleaners, clobetasol and fluocinonide ointments, triamcinolone ointment, hydrocortisone ointment, glycerol, hydroxyethylcellulose or soy products.
  4. Known recalcitrance to topical , including class 1 steroids, within 6 months of the Screening Visit.
  5. History of serious life-threatening reaction to tape or adhesives.
  6. Known allergy to all antibiotics to which S. hominis A9 is sensitive. These include ampicillin-sulbactam, cefazolin, cefoxitin, clindamycin, daptomycin, doxycycline, levofloxacin, linezolid, minocycline, moxifloxacin, mupirocin, nitrofurantoin, oxacillin, rifampin, trimethoprim-sulfamethoxazole, and vancomycin.
  7. Has a major defect in the epidermal barrier such as open wounds or genodermatoses (e.g., Netherton's syndrome).
  8. Is (e.g., (HIV)/Acquired Immunodeficiency Syndrome (AIDS), Wiskott-Aldrich Syndrome) or has an immune system disorder (e.g., disease).
  9. Has current malignant disease (except non-melanoma skin cancer in an area not affected by treatment).
  10. Has a history of psychiatric disease or history of alcohol or drug abuse that, in the opinion of the study investigator, would interfere with the ability to comply with the study protocol.
  11. Ongoing participation in another trial or use of investigational drugs within 8 weeks, or five half-lives (if known), whichever is longer, of the Screening Visit.
  12. Treatment with non-steroid systemic immunosuppressant within 6 months of the Screening Visit.
  13. Treatment with any biologic, including dupilumab, within 16 weeks of the Screening Visit.
  14. Treatment with oral or injectable therapy for AD (excluding oral steroids) within five half-lives (if known) or 16 weeks before the Screening Visit, whichever is longer.
  15. Treatment with oral retinoids (e.g., isotretinoin) within 60 days of the Screening Visit.
  16. Treatment with allergen immunotherapy within 30 days of Screening Visit.
  17. Has close contacts (e.g., spouse, children, or members in the same household) who have severe barrier defects or are immunocompromised.
  18. May, in the opinion of the investigator, have difficulty tolerating the medication washout requirements for topical AD treatments, prescription moisturizers, antibiotics, oral steroid therapies, and phototherapy ahead of Baseline.
  19. Past or current medical conditions or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.

    Individuals who meet any of the following criteria at Baseline are not eligible for enrollment as study participants:

  20. Have more than 30% body surface area of AD involvement, as indicated by the derived total area of involvement score during SCORAD assessment.
  21. Active bacterial, viral, or fungal skin infections, except for onychomycosis and tinea pedis.
  22. Any noticeable breaks or cracks in the skin on the target areas of investigational product application, including severely excoriated skin or skin with open or weeping wounds suggestive of an active infection.

    a. At the investigator's discretion, participants with minor breaks, cracks, or excoriations on body areas not eligible for sampling during the trial may be enrolled, provided there is no evidence of infection and investigational product is not applied to these areas until healed.

  23. Use of topical AD treatments - including steroids and calcineurin inhibitors - on the upper extremities (exclusive of the hands), lower extremities (exclusive of the feet), or trunk within seven days of the Baseline Visit.
  24. Treatment with prescription moisturizers classified as medical device (e.g., Atopiclair®, MimyX®, Epiceram®, etc.) on the upper extremities (exclusive of the hands), lower extremities (exclusive of the feet), or trunk within seven days of the Baseline Visit.
  25. Use of any systemic microbialª within fourteen days of the Baseline Visit, or use of any topical antimicrobial on the upper extremities (exclusive of the hands), lower extremities (exclusive of the feet), or trunk within fourteen days of the Baseline Visit.

    a. Antimicrobials include antibiotics, antifungals, antiparasitics, and antivirals. Certain systemic antivirals that do not exhibit systemic anti-inflammatory effects may be permitted with prior approval from a protocol co-chair).

  26. Within the upper extremities (exclusive of the hands), lower extremities (exclusive of the feet), and trunk, use of topical products - prescription or over-the-counter, all formulations - not specified per protocol, within seven days of the Baseline Visit.
  27. Use of systemic corticosteroid therapies for any indication within 28 days of the Baseline Visit.
  28. Use of systemic corticosteroid therapies for treatment of an asthma exacerbation within 3 months of the Baseline Visit.
  29. Require a dose greater than 880 mcg/day of fluticasone propionate or equivalent inhaled corticosteroid to maintain asthma control, at the time of the Baseline Visit.
  30. Any phototherapy for skin disease (such as narrow band ultraviolet B [NBUVB], ultraviolet B [UVB], ultraviolet A1 [UVA1], psoralen + UVA [PUVA]) or regular use (more than 2 visits per week) of a tanning bed within 28 days of the Baseline Visit.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
86 participants (estimated)

Study arms

  • Experimental
    ShA9 Topical Gel

    From baseline to Week 2, ShA9 and TCS will be applied twice daily to selected and new lesions; once treated, areas will continue treatment regardless of lesion status. Age 6-11: Triamcinolone will be applied before ShA9 in non-sensitive areas; hydrocortisone will be applied with ShA9 in sensitive areas. Age ≥12: Clobetasol (or fluocinonide, for participants intolerant to clobetasol) will be applied before ShA9 in non-sensitive areas; hydrocortisone will be applied with ShA9 in sensitive areas. After 2 weeks, all participants will continue applying ShA9 without TCS for 12 additional weeks, applying ShA9 to all previously treated and new lesions through Week 14 regardless of lesion status.

    Drug: ShA9 Topical Gel · Drug: Hydrocortisone Ointment · Drug: Clobetasol Ointment · Drug: Fluocinonide Ointment · Drug: Triamcinolone Ointment

  • Placebo comparator
    Placebo (Vehicle) Topical Gel

    From baseline to Week 2, placebo (vehicle) and TCS will be applied twice daily to selected and new lesions; once treated, areas will continue treatment regardless of lesion status. Age 6-11: Triamcinolone will be applied before placebo (vehicle) in non-sensitive areas; hydrocortisone will be applied with placebo (vehicle) in sensitive areas. Age ≥12: Clobetasol (or fluocinonide, if the participant is intolerant to clobetasol) will be applied before placebo (vehicle) in non-sensitive areas; hydrocortisone will be applied with placebo (vehicle) in sensitive areas. After 2 weeks, participants will continue placebo (vehicle) without TCS for 12 additional weeks, applying placebo (vehicle) to all previously treated and new lesions through Week 14 regardless of lesion status.

    Drug: Hydrocortisone Ointment · Drug: Clobetasol Ointment · Drug: Fluocinonide Ointment · Drug: Placebo (Vehicle) Topical Gel · Drug: Triamcinolone Ointment

Interventions

  • DrugShA9 Topical Gel

    The ShA9 topical gel contains phosphate-buffered saline solution (PBS), Glycerol, and hydroxyethylcellulose containing lyophilized ShA9 bacteria. The ShA9 bacteria is derived from a healthy donor-derived (allogeneic) commensal Staph species. The gel is manufactured and packaged by University of California San Diego (UCSD). It is applied twice daily to all areas identified as actively lesional during the Baseline Visit, regardless of ongoing lesional status, until the Week 14 Visit. If new lesions arise during this time, these areas will also be treated, regardless of ongoing lesional status, until the Week 14 Visit.

  • DrugHydrocortisoneStudies of HydrocortisoneHydrocortisone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants of all ages will apply hydrocortisone ointment 2.5% alongside the study product in sensitive body areas (e.g., face, neck, intertriginous regions) for the first two weeks of the trial. It is applied twice daily to all areas identified as actively lesional during the Baseline Visit, regardless of ongoing lesional status, until the Week 2 Visit. If new lesions arise during this time, these areas will also be treated, regardless of ongoing lesional status, until the Week 2 Visit.

  • DrugClobetasolStudies of ClobetasolClobetasol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants 12 years of age and older will apply clobetasol ointment 0.05% alongside the study product in non-sensitive body areas (e.g., arms, legs, torso) for the first two weeks of the trial. It will be applied twice daily to lesional skin and selected sampling areas from Baseline to Week 2. It is applied twice daily to all areas identified as actively lesional during the Baseline Visit, regardless of ongoing lesional status, until the Week 2 Visit. If new lesions arise during this time, these areas will also be treated, regardless of ongoing lesional status, until the Week 2 Visit.

  • DrugFluocinonideStudies of FluocinonideFluocinonide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants 12 years of age and older with a past intolerance to clobetasol or who become too sensitive to clobetasol in the initial two-week cotreatment period will apply fluocinonide ointment 0.05% as an alternative. In these cases, fluocinonide ointment 0.05% will be applied alongside the study product in non-sensitive body areas (e.g., arms, legs, torso) for the first two weeks of the trial. It is applied twice daily to all areas identified as actively lesional during the Baseline Visit, regardless of ongoing lesional status, until the Week 2 Visit. If new lesions arise during this time, these areas will also be treated, regardless of ongoing lesional status, until the Week 2 Visit.

  • DrugPlacebo (Vehicle) Topical Gel

    The placebo (vehicle) topical gel contains phosphate-buffered saline solution (PBS), Glycerol, and hydroxyethylcellulose. The gel is manufactured and packaged by University of California San Diego (UCSD). It is applied twice daily to all areas identified as actively lesional during the Baseline Visit, regardless of ongoing lesional status, until the Week 14 Visit. If new lesions arise during this time, these areas will also be treated, regardless of ongoing lesional status, until the Week 14 Visit.

  • DrugTriamcinoloneStudies of TriamcinoloneTriamcinolone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants 6 to 11 years of age will apply triamcinolone ointment 0.025% alongside the study product in non-sensitive body areas (e.g., arms, legs, torso) for the first two weeks of the trial. It is applied twice daily to all areas identified as actively lesional during the Baseline Visit, regardless of ongoing lesional status, until the Week 2 Visit. If new lesions arise during this time, these areas will also be treated, regardless of ongoing lesional status, until the Week 2 Visit.

06

What researchers measure

Primary outcomes

  1. Time to the first Atopic Dermatitis (AD) flare.

    Time (in days) to the first Atopic Dermatitis (AD) flare, indicated by having an Investigator Global Assessment (IGA) score that is greater than or equal to 2 and greater than the IGA score determined at Week 2. The IGA score is used to describe the overall appearance of AD lesions on a scale of 0 (clear) to 4 (severe).

    Time frame: Week 2 (exclusive) through Week 14 (inclusive)

  2. Serious and non-serious treatment-emergent adverse events (TEAEs) related or possibly related to study treatment.

    The number of serious and non-serious treatment-emergent adverse events (TEAEs) related or possibly related to study treatment. If a participant experiences the same TEAE on multiple occasions, the event will be counted once for each occurrence when reporting the number of TEAEs.

    Time frame: Baseline through Week 14

Secondary outcomes

  1. Serious and non-serious TEAEs related or possibly related to study treatment.

    The number of serious and non-serious TEAEs related or possibly related to study treatment. If a participant experiences the same TEAE on multiple occasions, the event will be counted once for each occurrence when reporting the number of TEAEs.

    Time frame: Week 14 (exclusive) through Week 18

  2. Antibiotic sensitivity of S. aureus and S. epidermidis on the skin.

    The proportion of the skin bacteria, S. aureus and S. epidermidis, which can be isolated from skin swabs, that are sensitive to each of the following antibiotics: penicillin G, tetracycline, and erythromycin at Week 14 (post-ShA9 treatment) adjusted for the proportion of bacteria sensitive to antibiotic at Baseline.

    Time frame: Baseline, Week 14

  3. Change in total Eczema Area and Severity Index (EASI) score.

    The change in total Eczema Area and Severity Index (EASI) score, which measures physical signs of atopic dermatitis, including area of involvement and severity (range: 0-72). Severity components include erythema, papulation, excoriation, and lichenification (0=absent, 1=mild, 2=moderate, 3=severe) for each body region (head/neck, trunk, arms, legs). Area of involvement (%) is assessed for each body region. Area and severity of each body region is weighted based on size of region, and region scores are added for a total EASI score (≤7=mild, \>7 and ≤21.1=moderate, \>21.1=severe). Descriptive note regarding time frame: if a participant was rescued with TCS within 14 days prior to their Week 14 visit, then their total EASI score at this timepoint will not be considered. Instead, the most recent total EASI score before the use of rescue TCS will be carried forward to represent Week 14.

    Time frame: Baseline, Week 14

  4. EASI 50

    The proportion of participants who achieve 50% or more reduction in their total EASI score. Descriptive note regarding time frame: if a participant was rescued with TCS within 14 days prior to their Week 14 visit, then their total EASI score at this timepoint will not be considered. Instead, the most recent total EASI score before the use of rescue TCS will be carried forward to represent Week 14.

    Time frame: Baseline, Week 14

  5. EASI 75

    The proportion of participants who achieve 75% or more reduction in their total EASI score. Descriptive note regarding time frame: if a participant was rescued with TCS within 14 days prior to their Week 14 visit, then their total EASI score at this timepoint will not be considered. Instead, the most recent total EASI score before the use of rescue TCS will be carried forward to represent Week 14.

    Time frame: Baseline, Week 14

  6. Change in IGA score

    The change in IGA score. The IGA score is used to describe the overall appearance of AD lesions on a scale of 0 (clear) to 4 (severe). Descriptive note regarding time frame: if a participant was rescued with TCS within 14 days prior to their Week 14 visit, then their IGA score at this timepoint will not be considered. Instead, the most recent IGA score before the use of rescue TCS will be carried forward to represent Week 14.

    Time frame: Baseline, Week 14

  7. Change in Pruritus Numeric Rating Scale (NRS) score.

    The change in Pruritus Numeric Rating Scale (NRS) score, which measures the average intensity of a pruritus (itch) during a 24-hour recall period on a scale of 0 (none) to 10 (worst imaginable itch). Descriptive note regarding time frame: if a participant was rescued with TCS within 14 days prior to their Week 14 visit, then their NRS score at this timepoint will not be considered. Instead, the most recent NRS score before the use of rescue TCS will be carried forward to represent Week 14.

    Time frame: Baseline, Week 14

  8. Change in SCORing Atopic Dermatitis (SCORAD) score.

    The change in SCORing Atopic Dermatitis (SCORAD) score, which ranges from 0 (no AD) to 103 (severe). SCORAD is a composite index comprising a) the amount/extent of body surface area affected, b) subjective symptom visual analog assessments of itch and sleep loss, each on a scale of 0 (none) to 10 (worst imaginable), and c) 6 disease intensity assessments: dryness, erythema, edema/papulation, excoriation, lichenification and oozing/crusting, each graded from 0 (none) to 3 (severe). Descriptive note regarding time frame: if a participant was rescued with TCS within 14 days prior to their Week 14 visit, then their SCORAD score at this timepoint will not be considered. Instead, the most recent SCORAD score before the use of rescue TCS will be carried forward to represent Week 14.

    Time frame: Baseline, Week 14

  9. Duration of rescue topical corticosteroid (TCS) use.

    The total number of days that topical corticosteroid (TCS) was used as a rescue medication within the upper extremities, lower extremities, and trunk of the body region, overall and separated by the potency class of steroids. The decision to begin the rescue TCS regimen due to skin exacerbation is dependent on investigator assessment, self-reported participant need, and standard of care.

    Time frame: Week 2 (exclusive) through Week 14 (inclusive)

  10. Time to the first reported use of rescue TCS.

    Time (in days) to the first reported use of rescue TCS. The decision to begin the rescue TCS regimen due to skin exacerbation is dependent on investigator assessment, self-reported participant need, and standard of care.

    Time frame: Week 2 (exclusive) through Week 14 (inclusive)

07

Study locations

7 of 8 sites recruiting
  • University of California, San Diego: Dermatology Clinical Trials Unit
    San Diego, California 92093, United States
    Recruiting
    • Alexandra Fernandez-Desoto · Contactalf013@health.ucsd.edu · 858-657-8390
    • Tissa Hata, MD · Principal investigator
  • National Jewish Health: Division of Pediatric Allergy and Clinical Immunology
    Denver, Colorado 80206, United States
    Recruiting
    • Tyler Swenson · Contactswensont@njhealth.org · 303-398-1409
    • Donald Leung, MD · Principal investigator
  • Northwestern University Feinberg School of Medicine: Department of Dermatology
    Chicago, Illinois 60611, United States
    Recruiting
  • New York University Langone Health: Department of Pediatric Allergy and Immunology
    New York, New York 10016, United States
    Terminated

    Not enrolling at this site.

  • Icahn School of Medicine at Mount Sinai: Department of Pediatrics Allergy & Immunology
    New York, New York 10029, United States
    Recruiting
  • University of Rochester Medical Center: Department of Dermatology
    Rochester, New York 10029, United States
    Recruiting
  • Cincinnati Children's Hospital Medical Center: Asthma Center
    Cincinnati, Ohio 45229, United States
    Recruiting
  • University of Wisconsin School of Medicine and Public Health: Division of Pediatric Allergy, Immunology and Rheumatology
    Madison, Wisconsin 53792, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Share data upon study completion in Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.

Time frame: Post database lock

Access criteria: Open Access

Data sharing details ↗ · www.immport.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.

Of 131 phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's planned 19 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2024
First posted
Jul 16, 2024
StartActual
May 22, 2025
Primary completionEst.
Dec 24, 2026
CompletionEst.
Feb 5, 2027
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06504160
Collaborators
Atopic Dermatitis Research Network (ADRN), Rho Federal Systems Division, Inc., PPD, Thermo Fisher Scientific Inc.
Responsible party
Sponsor
First posted
Jul 16, 2024
Start date
May 22, 2025
Primary completion
Dec 24, 2026 (estimated)
Completion
Feb 5, 2027 (estimated)
Last update
Jul 2, 2026

Study contacts

Richard Gallo, MD, PhD
study chair · University of California, San Diego: Dermatology Clinical Trials Unit
Tissa Hata, MD
study chair · University of California, San Diego: Dermatology Clinical Trials Unit
Donald Leung, MD, PhD
study chair · National Jewish Health: Division of Pediatric Allergy and Clinical Immunology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion